Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
6.
Clin Exp Dermatol ; 39(7): 813-5, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25156341

ABSTRACT

Golimumab is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti-TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.


Subject(s)
Antibodies, Monoclonal/adverse effects , Dermatitis, Exfoliative/chemically induced , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...